The known relevance of CD6-CD166/ALCAM interaction in cell-to-cell adhesive contacts established between T cells and other immune (B cells, macrophages, dendritic cells) and non-immune (endothelial, epithelial) cells warrants future studies of CD6 variation in cancer. This evidence concerns the gene ALCAM and cancer.